Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells

Journal of Immunology

Volumn 165, Issue 2, 2000, Pages 888-895

  Cochlovius, Björn ^a   Kipriyanov, Sergey M ^a,b   Stassar, Marike J J G ^a   Christ, Oliver ^a   Schuhmacher, Jochen ^a   Strauß, Gudrun ^a   Moldenhauer, Gerhard ^a   Little, Melvyn ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Affimed GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD19; MONOCLONAL ANTIBODY CD3; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CYTOLYSIS; DRUG STABILITY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; XENOGRAFT;

EID: 0034662031     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.2.888     Document Type: Article

References (52)

1. Fanger, M. W., P. M. Morganelli, and P. M. Guyre. 1992. Bispecific antibodies. Crit. Rev. Immunol. 12:101.
2. Canevari, S., G. Stoter, F. Arienti, G. Bolis, M. I. Colnaghi, E. M. D. Re, A. M. M. Eggermont, S. H. Goey, J. W. Grazama, C. H. J. Lamers, et al. 1995. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 87:1463.
3. Nitta, T., K. Sato, H. Yagita, K. Okumura, and S. Ishi. 1990. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335:368.
4. Grossbard, M. L., O. W. Press, F. R. Appelbaum, I. D. Bernstein, and L. M. Nadler. 1992. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863.
5. Bohlen, H., T. Hopff, O. Manzke, A. Engert, D. Kube, P. D. Wickramanayake, V. Diehl, and H. Tesch. 1993. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 82:1803.
6. Brennan, M., P. F. Davidson, and H. Paulus. 1985. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229:81.
7. 2 antibody containing thioetherlinked Fab'γ fragments. J. Immunol. 139:2367.
8. Khazaeli, M. B., R. M. Conry, and A. F. LoBuglio. 1994. Human immune response to monoclonal antibodies. J. Immunother. 15:42.
9. Carter, P., J. Ridgway, and Z. Zhu. 1995. Toward the production of bispecific antibody fragments for clinical applications. J. Hematother. 4:463.
10. Plückthun, A., and P. Pack. 1997. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3:83.
11. De Kruif, J., and T. Logtenberg. 1996. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J. Biol. Chem. 271:7630.
12. L) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett. 422:259.
13. Gruber, M., B. A. Schodin, E. R. Wilson, and D. M. Kranz. 1994. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J. Immunol. 152:5368.
14. Kurucz, I., J. A. Titus, C. R. Jost, C. M. Jacobus, and D. M. Segal. 1995. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria. J. Immunol. 154:4576.
15. Holliger, P., T. Prospero, and G. Winter. 1993. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90:6444.
16. Holliger, P., J. Brissinck, R. L. Williams, K. Thielemans, and G. Winter. 1996. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng. 9:299.
17. Zhu, Z., G. Zapata, R. Shalaby, B. Snedecor, H. Chen, and P. Carter. 1996. High level secretion of a humanized bispecific diabody from Escherichia coli. Bio/ Technology 14:192.
18. Perisic, O., P. A. Webb, P. Holliger, G. Winter, and R. L. Williams. 1994. Crystal structure of a diabody, a bivalent antibody fragment. Structure 2:1217.
19. Kipriyanov, S. M., G. Moldenhauer, G. Strauss, and M. Little. 1998. Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells. Int. J. Cancer 77:763.
20. Horn, U., W. Strittmatter, A. Krebber, U. Knupfer, M. Kujau, R. Wenderoth, K. Müller, S. Matzku, A. Plückthun, and D. Riesenberg. 1996. High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions. Appl. Microbiol. Biotechnol. 46:524.
21. Bothmann, H., and A. Plückthun. 1998. Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nat. Biotechnol. 16:376.
22. Holck, A., and K. Kleppe. 1988. Cloning and sequencing of the gene for the DNA-binding 17K protein of Escherichia coli. Gene 67:117.
23. Thisted, T., N. S. Sorensen, E. G. Wagner, and K. Gerdes. 1994. Mechanism of post-segregational killing: Sok antisense RNA interacts with Hok mRNA via its 5′-end single-stranded leader and competes with the 3′-end of Hok mRNA for binding to the mok translational initiation region. EMBO J. 13:1960.
24. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463.
25. R3 and autogenous negative control by represser. J. Mol. Biol. 139:147.
26. Blackwell, J. R., and R. Horgan. 1991. A novel strategy for production of a highly expressed recombinant protein in an active form. FEBS Lett. 295:10.
27. Kipriyanov, S. M., G. Moldenhauer, and M. Little. 1997. High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. J. Immunol. Methods 200:69.
28. Kipriyanov, S. M., G. Moldenhauer, A. C. R. Martin, O. A. Kupriyanova, and M. Little. 1997. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng. 10:445.
29. Kipriyanov, S. M., O. A. Kupriyanova, M. Little, and G. Moldenhauer. 1996. Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry. J. Immunol. Methods 196:51.
30. Schodin, B. A., and D. M. Kranz. 1993. Binding affinity and inhibitory properties of a single-chain anti-T cell receptor antibody. J. Biol. Chem. 268:25722.
31. Adair, J. R., D. S. Athwal, M. Bodmer, S. M. Bright, A. Collins, V. L. Pulito, P. E. Rao, R. Reedman, A. L. Rothermel, D. Xu, et al. 1994. Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Hum. Antibodies Hybridomas 5:41.
32. Adams, G. P., R. Schier, K. Marshall, E. J. Wolf, A. M. McCall, J. D. Marks, and L. M. Weiner. 1998. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58:485.
33. Matzinger, P. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145:185.
34. Kipriyanov, S. M., S. Dübel, F. Breitling, R. E. Kontermann, and M. Little. 1994. Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: production of bivalent and biotinylated miniantibodies. Mol. Immunol. 31:1047.
35. Csóka, M., G. Strauss, K.-M. Debatin, and G. Moldenhauer. 1996. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3 × CD19 bispecific antibody. Leukemia 10:1765.
36. Davidian, M., and D. Giltinan. 1995. Nonlinear Models for Repeated Measurement Data. Chapman and Hall.
37. Pinheiro, J. C., and D. M. Bates. 2000. Mixed-effects models. In Statistics and Computing Series. Springer-Verlag, New York.
38. Pezzutto, A., B. Dörken, P. S. Rabinovitch, J. A. Ledbetter, G. Moldenhauer, and E. A. Clark. 1987. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J. Immunol. 138:2793.
39. Kung, P. C., G. Golstein, E. L. Reinherz, and S. F. Schlossman. 1979. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206:347.
40. Le Gall, F., S. M. Kipriyanov, G. Moldenhauer, and M. Little. 1999. Di-, tri-and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett. 453:164.
41. + tumor cells by an anti-CD3/CA 19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody. J. Immunother. 20:325.
42. Cochlovius, B., A. Perschl, G. J. Adema, and M. Zoller. 1999. Human melanoma therapy in the SCID mouse: in vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments. Int. J. Cancer 81:486.
43. Renner, C., W. Jung, U. Sahin, R. Denfeld, C. Pohl, L. Trumper, F. Hartmann, V. Diehl, R. van Lier, and M. Pfreundschuh. 1994. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264:833.
44. Hartmann, F., C. Renner, W. Jung, C. Deisting, M. Juwana, B. Eichentopf, M. Kloft, and M. Pfreundschuh. 1997. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89:2042.
45. Stockmeyer, B., T. Valerius, R. Repp, I. A. Heijnen, H. J. Buhring, Y. M. Deo, J. R. Kalden, M. Gramatzki, and J. G. van de Winkel. 1997. Preclinical studies with FcγR bispecific antibodies and granulocyle colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res. 57:696.
46. Valitutti, S., S. Muller, M. Cella, E. Padovan, and A. Lanzavecchia. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148.
47. Chambers, C. A., and J. P. Allison. 1999. Costimulatory regulation of T cell function. Curr. Opin. Cell Biol. 11:203.
48. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349.
49. Daniel, P. T., A. Kroidl, S. Cayeux, R. Bargou, T. Blankenstein, and B. Dorken. 1997. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J. Immunol. 159:3808.
50. Daniel, P. T., A. Kroidl, J. Kopp, I. Sturm, G. Moldenhauer, B. Dorken, and A. Pezzutto. 1998. Immunotherapy of B-cell lymphoma with CD3 × 19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood 92:4750.
51. Arndt, M. A., J. Krauss, S. M. Kipriyanov, M. Pfreundschuh, and M. Little. 1999. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplanted human Hodgkin's tumors. Blood 94:2562.
52. De Jonge, J., C. Heirman, M. de Veerman, S. Van Meirvenne, M. Moser, O. Leo, and K. Thielemans. 1998. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (ami-CD3 × anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. J. Immunol. 161:1454.